Mammalian tolloid proteinases: role in growth factor signalling

Helen Troilo1, Christopher P. Bayley1, Anne L. Barrett1, Michael P. Lockhart-Cairns1,2, Thomas A. Jowitt1 and Clair Baldock1

1 Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, UK
2 Beamline B21, Diamond Light Source, Harwell Science & Innovation Campus, Didcot, Oxfordshire, UK

Correspondence
C. Baldock, Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, Michael Smith Building, University of Manchester, Manchester M139PT, UK
Fax: +44 161 2755082
Tel: +44 161 2755439
E-mail: clair.baldock@manchester.ac.uk

(Received 12 June 2016, revised 30 June 2016, accepted 6 July 2016, available online 22 July 2016)
doi:10.1002/1873-3468.12287
Edited by Wilhelm Just

Tolloid proteinases are essential for tissue patterning and extracellular matrix assembly. The members of the family differ in their substrate specificity and activity, despite sharing similar domain organization. The mechanisms underlying substrate specificity and activity are complex, with variation between family members, and depend on both multimerization and substrate interaction. In addition, enhancers, such as Twisted gastrulation (Tsg), promote cleavage of tolloid substrate, chordin, to regulate growth factor signalling. Although Tsg and mammalian tolloid (mTLD) are involved in chordin cleavage, no interaction has been detected between them, suggesting Tsg induces a change in chordin to increase susceptibility to cleavage. All members of the tolloid family bind the N terminus of latent TGFβ-binding protein-1, providing support for their role in TGFβ signalling.

Keywords: BMP signalling; chordin; latent TGFβ-binding protein; twisted gastrulation

The mammalian tolloid family consists of four members: bone morphogenetic protein-1 (BMP-1), mammalian tolloid (mTLD) which are alternatively spliced products of the Bmp1 gene [1] and two genetically distinct proteins tolloid-like (TLL)-1 and TLL-2 [2,3]. Together they comprise a small group of zinc and calcium dependent proteinases [4]. BMP-1 is not a member of the BMP family of cytokines, it was initially copurified with BMP2 and BMP3 from extracts of bone and named accordingly [5], however, it had also been previously identified as procollagen C-proteinase [6]. The domain organization of mTLD, TLL-1 and TLL-2 is identical and this is evolutionarily conserved, for example, in Drosophila (dTLD) and Xenopus (Xld) [7]. This arrangement consists of an N-terminal protease domain, making tolloids part of the astacin superfamily [7], followed by up to five CUB (Complement, Uegf and BMP-1) modules and two calcium ion binding epidermal growth factor (EGF)-like domains (Fig. 1).

Interestingly, BMP-1 (the shorter splice variant), which is generally the most active tolloid and cleaves a wide range of substrates, is expressed without the final three noncatalytic domains. It was shown through biophysical and structural methods that mTLD and TLL-1 form noncovalently linked Ca2+-dependent dimers in solution, whereas BMP-1 and TLL-2 remain as monomers [8–10]. It has been demonstrated that substrate exclusion due to dimerization results in reduced activity of these proteinases in comparison to BMP-1 [9,10]. However, TLL-2 is predominantly monomeric in solution so its activity must be modulated by

Abbreviations
BMP-1, bone morphogenetic protein-1; CR, cysteine-rich; ECM, extracellular matrix; EGF, epidermal growth factor; LAP, latency-associated protein; LLC, large latent complexes; MMPs, matrix metalloproteinases; mTLD, mammalian tolloid; ONT1, olfactomedin 1; PCPE-1, procollagen C-endopeptidase enhancer-1; sFRP2, secreted frizzled-related protein 2; SLC, small latent complex; TGF, transforming growth factor; TLL, tolloid-like; Tsg, twisted gastrulation; vWFC, von Willebrand Factor type C.
another mechanism. The noncatalytic domains appear to function by restricting proteolytic activity both in terms of substrate specificity [11] and efficiency by exosite binding [9]. Additionally, C-terminal truncation of TLL-2 and drosophila TLD (dTLD) results in the loss of activity [8,11,12]. However, C-terminal truncation of TLL-1 and mTLD increases their activity against some substrates [9,10,13]. Furthermore, when secreted alone in vitro, the BMP-1/mTLD protease domain cleaves additional sites in previously characterized substrates and also cleaves other matrix proteins such as fibronectin, which are left intact by the full-length protease [13]. BMP-1/mTLD act on a wide-range of substrates including extracellular matrix precursors and BMP/TGFβ regulators.

**Tolloid substrates**

In vertebrates, BMP-1/mTLD proteinases are involved in the biosynthetic processing of a diverse range of extracellular matrix (ECM) precursors required for laying down the extracellular matrix and normal tissue assembly (Fig. 2). Substrates include the major and minor fibrillar procollagens [14–16], the collagen and elastin crosslinking enzyme prolysyl oxidase [17], cellular anchoring proteins prolaminin-5 and procollagen VII [18,19] and the small leucine-rich proteoglycans, osteoglycin and probiglycan [20,21]. Mutations in BMP-1/mTLD have been shown to cause osteogenesis imperfecta (OI), a disease primarily characterized by fragile bones that have a high susceptibility to fracture, along with neurological impairments [22,23]. Martinez-Glez et al. reported that the F249L missense mutation in BMP-1/mTLD decreased the ability for procollagen I C-propeptide to be processed correctly resulting in the OI phenotype [23] demonstrating the essential role of tolloids in collagen processing. In addition to processing precursor proteins to their mature form, cleavage of mature proteins by tolloids can give rise to fragments with novel biological functions, for example, cleavage of endorepellin gives rise to the angiostatic LG3 fragment [24]. BMP-1/mTLD proteinases are also instrumental in the release a number of transforming growth factor (TGF)-β superfamily members from inhibitory complexes, including BMP-2, -4 and 7, growth and differentiation factors 8/11 and TGFβ1. This action modulates developmental patterning, growth of skeletal muscle, and tissue homoeostasis respectively [3,25–27].

**Role of tolloids in BMP and TGFβ signalling**

Through the proteolytic cleavage of their substrates BMP-1/mTLD modify matrix components thereby regulating many cellular activities such as proliferation and differentiation. BMP-1/mTLD are involved in the regulation of dorso-ventral patterning through the cleavage of the BMP antagonist chordin (Fig. 2). BMPs are a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. They were not only identified for their function in bone and cartilage formation but also have roles in patterning, kidney, eye and heart formation [28,29]. Chordin functions as an extracellular antagonist of BMP-2, -4 and -7 by binding to them and preventing their interaction with the BMP receptors [30]. Cleavage of the BMP-chordin complex by BMP-1/mTLD proteinases liberates BMP, resulting in downstream signalling events including the generation of BMP gradients. In addition, tolloids are involved in the proteolytic release mechanism of active TGFβ1 growth factor from the latent complexes by providing the precipitating cleavage events which leave the remaining complex susceptible to MMPs [25,31].

**Fig. 1.** Schematic diagram of the domain structures of tolloid family members and chordin. The tolloids are composed of a protease domain followed by CUB and EGF domains. BMP-1 lacks the last three noncatalytic EGF and CUB domains. ‘T’ represents a unique C-terminal sequence. Chordin is composed of four von Willebrand factor type C domains and chordin specific or CHRD domains. Tolloids cleave chordin after vWC domains -1 and -3 (indicated by an arrow).
**Tolloid enhancers**

The activity of BMP-1/mTLD is modified by substrate-specific enhancers. Procollagen C-endopeptidase enhancer-1 (PCPE-1) is a CUB domain containing protein that enhances cleavage of fibrillar procollagens by BMP-1/TLD, however, PCPE-1 does not enhance cleavage of other tolloid substrates [32]. PCPE-1 binds directly to procollagen and cleavage of procollagen by mammalian tolloid is enhanced by as much 10-fold by PCPE-1 [33]. To add a further layer of complexity, PCPE binds heparan sulphate proteoglycans (such as syndecans) [34] and BMP1 procollagen cleavage can be super-stimulated by heparan sulphate [35]. These data suggest that scaffolding at the cell surface by heparan sulphate proteoglycans might allow accelerated procollagen processing by BMP1/mTLD and thus collagen assembly. Twisted gastrulation (Tsg) is a noncatalytic ECM glycoprotein important for skeletogenesis [36] and maintaining bone mineral density [37]. Tsg can act as a BMP antagonist by enhancing chordin/BMP complex formation [38–40]. Interestingly, Tsg can also act as a BMP agonist, by enhancing the cleavage of chordin relieving the inhibition of BMP signalling [41]. Other examples include the scaffolding protein, Olfactomedin 1 (ONT1), which functions by binding to both tolloid and substrate, bringing them into close proximity to enhance the rate of cleavage [42] and secreted frizzled-related protein 2 (sFRP2) which enhances procollagen protease activity in mammals [43]. However, in xenopus and zebrafish the sFRP, Sizzled, was shown to inhibit tolloid processing of chordin [44,45], indicating that the function of these regulators is not conserved.

This review will discuss the role of tolloid family proteases in the regulation of TGFβ-superfamily growth factor signalling. Specifically (1): how tolloid cleavage of chordin is enhanced by twisted gastrulation to result in the release of active growth factor, and (2) the role of tolloid cleavage of the large latent TGFβ complex in proteolytic activation of TGFβ1. Through these pathways tolloids function not only by activating matrix proteins following secretion but also as vital regulators in development and homoeostasis.

**Enhancing tolloid cleavage by twisted gastrulation**

**Role of tolloid as a BMP agonist**

The TGFβ/BMP signalling pathways control a myriad of events, including cell proliferation, differentiation, apoptosis, migration, ECM remodelling and tumour invasion/metastasis [46]. During embryogenesis of vertebrates and invertebrates, antagonism between BMPs and chordin is a general mechanism by which the dorso-ventral axis is established [47]. Chordin, BMPs and Tsg form a tripartite complex which can diffuse through the extracellular space. While BMPs are bound to chordin they are unable to bind to their cell surface receptors (BMPR) type I and II [30,48,49]. Cleavage of chordin by tolloids allows for BMPs to be released exerting a dorsal-ventral patterning effect, in vertebrates [3,50] and other organisms [51–53] through the SMAD or MAD pathways. In addition to its important developmental role, chordin is also involved in adult processes as it is expressed by chondrocytes during cartilage formation following bone fracture [54]. Chordin also has a role in the osteoarthritic process as higher protein levels are found in osteoarthritis than in normal cartilage [55].

**Cleavage of chordin by tolloid family proteinases**

Chordin, a 100 kDa glycoprotein, has a modular domain architecture consisting of four domains homologous to von Willebrand Factor type C (vWFC)
domains, sometimes also referred to as Cysteine-Rich (CR) domains, and four chordin specific or CHRD domains which are also cysteine-rich (Fig. 1). Chordin adopts a horseshoe shaped structure in which the four CHRD domains separate the first and second vWFC domains [56]. The first and third vWFC domains bind to BMP-2 and -4 [48], and the first and fourth vWFC domains bind BMP-7 [49]. The CHRD domains act as spacers, supporting a horseshoe shaped structure of chordin which facilitates simultaneous binding by the N- and C-terminal vWFC domains to the BMP ligand [56]. Cleavage of chordin by tolloid proteinases occurs at two specific interdomain sites following the first and third vWFC domains [57]. BMP-1 and TLL-1 cleave chordin with the greatest efficiency [3,9,10], whereas mTLD and TLL-2 are less active [8]. However, the noncatalytic domains of all mammalian tolloids bind to chordin with high affinity [8].

Since the biological activity of the individual vWFC domains is 5- to 10-fold lower than full-length chordin, it has been speculated that tolloid cleavage would release lower affinity vWFC-BMP complexes [48]. However, the affinity of the cleavage fragments is very similar to full-length chordin, and these fragments retain or even enhance BMP inhibitory activity, suggesting cleavage of both sites may be required for ablation of BMP inhibition by chordin [56,58–60]. One role for chordin is that beyond simply sequestering BMP in the tissue where it is expressed, chordin facilitates diffusion of BMP to other tissues [61]. The result is localized build-up of inactive BMP, in preparation for tolloid cleavage. This allows spatially and temporally controlled liberation of BMP from this complex allowing localized pockets of BMP activity at the dorsal pole of the embryo [62,63]. This model is supported by research in Drosophila, where a complex of the chordin-BMP-TLD homologues is assembled on collagen IV and mobilized by Tsg [11,64].

Enhancement of tolloid cleavage by Tsg

Tsg is a 33 kDa monomeric glycoprotein [59], identified as essential for the correct formation of the dorsal-ventral axis [65]. It is important for skeletogenesis [36] and maintaining bone mineral density in adulthood [37]. It has two cysteine-rich domains, one of which is homologous to vWFC domains [66]. Tsg has been shown to act in both a pro-BMP and anti-BMP manner. Tsg can act as a BMP-antagonist by binding to both chordin and BMP, enhancing chordin-BMP complex formation [38–40]. Consistent with this function, Tsg potentiates chordin’s ability to induce a secondary axis in Xenopus embryos [38]. Tsg binds to the chordin vWFC-2 and -3 domains with high-affinity and interacts more weakly to vWFC-1 and -4 [59].

Tsg acts as a BMP agonist by enhancing the cleavage of chordin by tolloid proteinases [41,67]. Tsg does not bind directly to tolloid proteinases and in vitro it can enhance tolloid cleavage of chordin in the absence of other factors so it must potentiate this enhancing effect through interaction with chordin [59]. There is evidence that Tsg may induce conformational changes in chordin that lead to increased cleavage. Mouse chordin has a third tolloid cleavage site in addition to the two highly conserved sites. Cleavage of this third site was only observed in vitro in the presence of Tsg [38], suggesting that this is a cryptic cleavage site inaccessible to tolloid proteinases in the absence of Tsg. Similarly, the presence of Tsg also alters the cleavage fragments observed following cleavage of the Drosophila chordin homologue Sog by dTLD in vitro [68]. The tolloid proteinases appear key to this switch in BMP regulation by Tsg, as was supported by RNA injection experiment studies in Xenopus. In dorsoized Xenopus embryos, the injection of Xolloid or Tsg mRNA rescues the formation of ventral trunk-tail structures normally seen in regions of high BMP signalling [41]. However, coinjection with dominant negative Xolloid mRNA, Tsg mRNA loses its pro-BMP ventralizing ability [41].

In mammals, Tsg is strongly expressed in cartilage and is involved in chondrocyte differentiation, playing an important role in cartilage development [69]. Tsg null mice display a dwarfism phenotype and osteopenia, due to defective chondrogenesis and endochondral ossification [36,70,71]. The tolloid metalloproteinases are known to be a key to bone and cartilage formation, and BMP-1, mTLD and TLL-1 are expressed in developing bone and cartilage in mice [3]. In the chick upregulation of tolloid gene expression precedes chondrogenic differentiation [72,73]. Indeed, BMP-1 can induce ectopic cartilage formation in vivo [5]. Hence, Tsg appears to be important during cartilage formation due to its promotion of BMP signalling via the enhancement of tolloid metalloproteinase activity. The importance of Tsg as a tolloid enhancer is highlighted by the pathologies that result from its absence.

Tolloid cleavage of the large latent TGFβ complex

Role of tolloids in TGFβ signalling

All TGFβ isoforms can be secreted as large latent complexes (LLC) which are not able to activate downstream signalling. They consist of three components: a
disulphide bonded homodimer of mature TGFβ, associated noncovalently with its latency-associated protein (LAP) which together comprise the small latent complex (SLC). The SLC is covalently linked by a disulphide bond to latent TGFβ-binding protein (LTBP) \[74,75\]. LTBPs are large extracellular matrix modular glycoproteins \[76\] with an important role in the processing and secretion of TGFβ. In many cell types, the expression of LTBP1 is coregulated with TGFβ1 \[77\] and a lack of LTBP-1 or -3 directly correlates with decreased TGFβ activation \[78,79\]. In addition, LTBP1 targets TGFβ to the ECM and is covalently linked to extracellular matrix fibrils by transglutaminase-2 cross-links \[80\].

Interestingly, the methods through which tolloids activate TGFβ differ from the mechanisms through which they regulate BMPs. Unlike chordin, LAP is not itself a tolloid substrate, nevertheless tolloids have a key role in regulating TGFβ activation, contributing to the release of latent TGFβ from the extracellular matrix through cleavage of LTBP-1 \[25\]. It also deactivates the soluble form of the TGFβ coreceptor betaglycan through proteolytic cleavage, thereby increasing TGFβ bioavailability \[81\]. Active TGFβ is a potent inducer of tolloid expression and it is expected that this contributes to a positive feedback loop of TGFβ signalling in inflammation and fibrosis \[25\].

**Activation of TGFβ by proteases and integrins**

A variety of physiological methods of releasing TGFβ from the LLC have been suggested (for review see \[82\]). Integrin-mediated activation appears to have a major role. LAPs from TGFβ1 and -3 have integrin-binding motifs and mutation of this sequence in TGFβ1 phenocopies the TGFβ1 null mice \[83\]. Integrin αβ6 binds and activates TGFβ but interaction of the LLC with fibronectin is required \[84\]. Force unfolding of LAP is thought to be the underlying mechanism in integrin activation events \[85,86\]. A short region in the N terminus of LTBP1 (amino acid residues 402–529) coupled to the C-terminal TGFβ1-binding domain of LTBP1 is sufficient to permit activation \[87\] suggesting that simultaneous binding between integrins to LAP and LTBP1 to other matrix components is required.

---

**Fig. 3.** Surface Plasmon resonance binding analysis of interactions between LTBP1 and mammalian tolloids. Domain structure of human LTBP1. EGF domains are shown as rectangles, TGFβ binding-like (TB) domains as ovals and a hybrid EGF/TB domain is represented as a pentamer. The LTBP1 N-terminal (NT) and C-terminal (CT) constructs are shown coloured in blue and orange respectively. (A) Binding analysis of full-length LTBP1 to immobilized protein fragment CUB1CUB2EGF1 from BMP-1/mTLD. Analyte concentrations = 0–40 nM. The real-time binding curves are shown in black and the model of Langmuir off-rate analysis is shown in red. Experiments performed in triplicate, representative curves shown. (B) LTBP1 NT and LTBP1 CT regions binding to immobilized CUB4CUB5 from mTLD, TLL-1 or TLL-2. LTBP1 NT binding in blue, CT binding in orange. Analyte concentration = 500 nM. Methods and experimental details are reported in \[10\].
Several proteases have also been implicated in activating latent TGFβ, including matrix metalloproteinases (MMPs) [88] and tolloid proteinases [25]. The recently solved structure of SLC shows that protease sensitive sites on LAP are surface accessible [85]. Tolloids cleave the LLC at two sites on LTBP1 but do not cleave LAP. Following tolloid cleavage, LAP (still bound to the LLC) is a substrate for MMPs, the action of which may subsequently release TGFβ [25,31].Interestingly, in the absence of TGFβ, BMP-1 did not cleave LTBP-1 but only when it was part of the LLC.

Mammalian tolloids bind to the N-terminal region of LTBP1

Since LTBP1 has previously been identified as a tolloid substrate, binding of full-length LTBP1 to the noncatalytic domains (CUB1CUB2EGF1) of BMP-1/mTLD was analysed by surface plasmon resonance. These data showed that BMP-1/mTLD bound to LTBP-1 (Fig. 3). To determine whether both N- and C-terminal regions of LTBP1 interacted with tolloids, these regions of LTBP-1 were screened for binding to the CUB4CUB5 domains of TLL-2, TLL-1 and mTLD. For the C-terminal LTBP-1 region no binding was detected to any protease. However, the N-terminal region of LTBP1 showed a stronger response (Fig. 3). This suggests that the C-terminal cleavage site either binds to other tolloid domains, or that tolloid binds exclusively at the N terminus and flexibility in LTBP-1 allows the protease access to both cleavage sites.

Consistent with previous findings BMP-1, mTLD and TLL-2 were unable to cleave LTBP1 when not covalently associated with LAP as part of the large latent complex (not shown). LTBP-1 is frequently expressed in the absence of the SLC and some members of the LTBP family are unable to bind SLC [89]. As cleavage by tolloids is specific to the LLC rather than free LTBP suggests that its regulatory role is targeted to the TGFβ pathway rather than also regulating TGFβ-independent functions of LTBPs [90–93].

Conclusions and perspectives

Tolloid family metalloproteases are key activators of TGFβ family of signalling molecules, an effect which is exerted through direct cleavage of inhibitors such as chordin and indirectly through cleavage of LTBPs. This role is regulated by modulators like Tsg resulting in precision in the activation of these signalling pathways. The tolloid family exert such a broad influence over matrix deposition and homeostasis that this is a promising pathway for future therapeutic intervention, for example, in cancers and bone disorders, however, it needs to be better understood. Further structural study of this family, in particular in complex with its binding partners is needed to enhance our knowledge of its regulation and context-dependent specificity.

Acknowledgements

We gratefully acknowledge funding from the BBSRC (Ref: BB/I012265/1) and Wellcome Trust (Ref: 106503/Z/14/Z).

Author contributions

HT, ALB, MPLC and CB wrote the paper. CPB and TAJ analysed data shown in Figure 3.

References

1 Takahara K, Lyons GE and Greenspan DS (1994) Bone morphogenetic protein-1 and a mammalian tolloid homologue (mTld) are encoded by alternatively spliced transcripts which are differentially expressed in some tissues. J Biol Chem 269, 32572–32578.
2 Takahara K, Brevard R, Hoffman GG, Suzuki N and Greenspan DS (1996) Characterization of a novel gene product (mammalian tolloid-like) with high sequence similarity to mammalian tolloid/bone morphogenetic protein-1. Genomics 34, 157–165.
3 Scott IC, Blitz IL, Pappano WN, Imamura Y, Clark TG, Steiglitz BM, Thomas CL, Maas SA, Takahara K, Cho KW et al. (1999) Mammalian BMP-1/Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis. Dev Biol 213, 283–300.
4 Mac Sweeney A, Gil-Parrado S, Vinzenz D, Bernardi A, Hein A, Bodendorf U, Erbel P, Logel C and Gerhartz B (2008) Structural basis for the substrate specificity of bone morphogenetic protein 1/tolloid-like metalloproteases. J Mol Biol 384, 228–239.
5 Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242, 1528–1534.
6 Miyahara M, Njieha FK and Prockop DJ (1982) Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem 257, 8442–8448.
7 Bond JS and Beynon RJ (1995) The astacin family of metalloendopeptidases. Protein Sci 4, 1247–1261.
Mammalian tolloid proteinases

H. Troilo et al.

8 Bayley CP, Ruiz Nivia HD, Dajani R, Jowitt TA, Collins RF, Rada H, Bird LE and Baldock C (2016) Diversity between mammalian tolloid proteinases: oligomerisation and non-catalytic domains influence activity and specificity. Sci Rep 6, 21456.

9 Berry R, Jowitt TA, Ferrand J, Roessle M, Grossmann JG, Canty-Laird EG, Kammerer RA, Kadler KE and Winstanley J, Sawala A, Baldock C and Ashe HL (2010) Structural and functional evidence for a substrate exclusion mechanism in mammalian tolloid like-1 (TLL-1) proteinase. FEBS Lett 584, 657–661.

10 Winstanley J, Sawalha A, Baldock C and Ashe HL (2015) Synthetic enzyme-substrate tethering obviates the Tolloid-ECM interaction during Drosophila BMP gradient formation. Elife 4, 05508.

11 Canty EG, Garrigue-Antar L and Kadler KE (2006) A complete domain structure of Drosophila tolloid is required for cleavage of short gastrulation. J Biol Chem 281, 13258–13267.

12 Wermter C, Howel M, Hintze V, Bombosch B, Aufenvenne K, Yiallouros I and Stocker W (2007) The protease domain of procollagen C-proteinase (BMP1) lacks substrate selectivity, which is conferred by non-proteolytic domains. Biol Chem 388, 513–521.

13 Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV and Prockop DJ (1996) The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenetic protein-1. Proc Natl Acad Sci USA 93, 5127–5130.

14 Medeck RJ, Sosa S, Morris N and Oxford JT (2003) BMP-1-mediated proteolytic processing of alternatively spliced isoforms of collagen type XI. Biochem J 376, 361–368.

15 Unsold C, Pappano WN, Imamura Y, Steiglitz BM and Greenspan DS (2002) Biosynthetic processing of the pro-alpha 1(V)2pro-alpha 2(V) collagen heterotrimer by bone morphogenetic protein-1 and furin-like proprotein convertases. J Biol Chem 277, 5596–5602.

16 Panchenko MV, Stetter-Stevenson WG, Trubitskoy OV, Gacheru SN and Kagan HM (1996) Metalloproteinase activity secreted by fibrogenic cells in the processing of procollagen alpha 1(V) collagen. Potential role of propeptide cleavage. J Biol Chem 271, 7113–7119.

17 Veitch DP, Nokelainen P, McGowan KA, Nguyen TT, Nguyen NE, Stephenson R, Pappano WN, Keene DR, Spong SM, Greenspan DS et al. (2003) Mammalian tolloid metalloproteinase, and not matrix metalloproteinase 2 or membrane type 1 metalloproteinase, processes laminin-5 in keratinocytes and skin. J Biol Chem 278, 15661–15668.

19 Rattenholl A, Pappano WN, Koch M, Keene DR, Kadler KE, Sasaki T, Timpl R, Burgeson RE, Greenspan DS and Bruckner-Tuderman L (2002) Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen. J Biol Chem 277, 26372–26378.

20 Ge G, Seo NS, Liang X, Hopkins DR, Hook M and Greenspan DS (2004) Bone morphogenic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem 279, 41626–41633.

21 Scott IC, Imamura Y, Pappano WN, Troedel JM, Recklies AD, Roughley PJ and Greenspan DS (2000) Bone morphogenetic protein-1 processes probiglycan. J Biol Chem 275, 30504–30511.

22 Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, Yigit G, Pohl E, Becker J, Frommolt P et al. (2012) Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet 90, 661–674.

23 Martinez-Glez V, Valencia M, Caparros-Martin JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D et al. (2012) Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 33, 343–350.

24 Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS and Ioizzo RV (2005) BMP-1/Tolloid-like metalloproteinases process endorepellin, the angiostatic C-terminal fragment of perlecian. J Biol Chem 280, 7080–7087.

25 Ge G and Greenspan DS (2006) BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 175, 111–120.

26 Ge G, Hopkins DR, Ho WB and Greenspan DS (2005) GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol 25, 5846–5858.

27 Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS et al. (2003) Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100, 15842–15846.

28 Dudley AT and Robertson EJ (1997) Overlapping expression domains of bone morphogenetic protein family members potentially account for limited tissue defects in BMP7 deficient embryos. Dev Dyn 208, 349–362.

29 Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S et al. (2014) Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Genes Dis 1, 87–105.
30 Piccolo S, Sasai Y, Lu B and De Robertis EM (1996) Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 86, 589–598.

31 Tatti O, Vehvilainen P, Lehti K and Keski-Oja J (2008) MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res 314, 2501–2514.

32 Moali C, Font B, Ruggiero F, Eichenberger D, Rousselle P, Francois V, Oldberg A, Bruckner-Tuderman L and Hulmes DJ (2005) Substrate-specific modulation of a multisubstrate proteinase. C-terminal processing of fibrillar procollagens is the only BMP-1-modulation of a multisubstrate proteinase. C-terminal processing of fibrillar procollagens is the only BMP-1-dependent activity to be enhanced by PCPE-1. J Biol Chem 280, 24188–24194.

33 Bourhis JM, Vadon-Le Goff S, Afrache H, Mariano N, Kronenberg D, Thielens N, Moali C and Hulmes DJ (2013) Procollagen C-proteinase enhancer grasps the stalk of the C-propeptide trimer to boost collagen precursor maturation. Proc Natl Acad Sci USA 110, 6394–6399.

34 Weiss T, Brusel M, Rousselle P and Kessler E (2014) The NTR domain of procollagen C-proteinase enhancer-1 (PCPE-1) mediates PCPE-1 binding to syndecans-1, -2 and -4 as well as fibronectin. Int J Biochem Cell Biol 57, 45–53.

35 Bekhouche M, Kronenberg D, Vadon-Le Goff S, Bijakowski C, Lim NH, Font B, Kessler E, Colige A, Nagase H, Murphy G et al. (2010) Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem 285, 15950–15959.

36 Nosaka T, Morita S, Kitamura H, Nakajima H, Shibata F, Morikawa Y, Kataoka Y, Ebihara Y, Kawashima T, Itoh T et al. (2003) Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol 23, 2969–2980.

37 Sotillo Rodriguez JE, Mansky KC, Jensen ED, Carlson AE, Schwarz T, Pham L, MacKenzie B, Prasad H, Rohrer MD, Petryk A et al. (2009) Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling. J Bone Miner Res 24, 1917–1926.

38 Scott IC, Blitz IL, Pappano WN, Maas SA, Cho KW and Greenspan DS (2001) Homologues of Twisted gastrulation are extracellular cofactors in antagonism of BMP signalling. Nature 410, 475–478.

39 Ross JJ, Shimmni O, Vilmos P, Petryk A, Kim H, Gaudenz K, Hermanson S, Ekker SC, O’Connor MB and Marsh JL (2001) Twisted gastrulation is a conserved extracellular BMP antagonist. Nature 410, 479–483.

40 Chang C, Holtzman DA, Chau S, Chickering T, Woolf EA, Holmgren LM, Bodorova J, Gearing DP, Holmes WE and Brivanlou AH (2001) Twisted gastrulation can function as a BMP antagonist. Nature 410, 483–487.

41 Larrain J, Oelgeschlager M, Kepurpa NI, Reversade B, Zakin L and De Robertis EM (2001) Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling. Development 128, 4439–4447.

42 Inomata H, Haraguchi T and Sasai Y (2008) Robust stability of the embryonic axial pattern requires a secreted scaffold for chordin degradation. Cell 134, 854–865.

43 Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, Yamada C, Liu TC, Huang G, Basson CT et al. (2009) Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 11, 46–55.

44 Lee HX, Ambrosio AL, Reversade B and De Robertis EM (2006) Embryonic dorsal-ventral signaling: secreted frizzled-related proteins as inhibitors of tolloid proteinases. Cell 124, 147–159.

45 Muruoka O, Shimizu T, Yabe T, Nojima H, Bae YK, Hashimoto H and Hibi M (2006) Sizzled controls dorso-ventral polarity by repressing cleavage of the Chordin protein. Nat Cell Biol 8, 329–338.

46 Wharton K and Derynck R (2009) TGFbeta family signaling: novel insights in development and disease. Development 136, 3691–3697.

47 De Robertis EM and Sasai Y (1996) A common plan for dorsoventral patterning in Bilateria. Nature 380, 37–40.

48 Larrain J, Bachiller D, Lu B, Agius E, Piccolo S and De Robertis EM (2000) BMP-binding modules in chordin: a model for signalling regulation in the extracellular space. Development 127, 821–830.

49 Zhang JL, Huang Y, Qiu LY, Nickel J and Sebald W (2007) von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J Biol Chem 282, 20002–20014.

50 Blader P, Rastegar S, Fischer N and Strahle U (1997) Cleavage of the BMP-4 antagonist chordin by zebrafish tolloid. Science 278, 1937–1940.

51 Marques G, Musacchio M, Shimell MJ, Wunkenberg-Stapleton K, Cho KW and O’Connor MB (1997) Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins. Cell 91, 417–426.

52 Akiyama-Oda Y and Oda H (2006) Axis specification in the spider embryo: dpp is required for radial-to-axial symmetry transformation and sog for ventral patterning. Development 133, 2347–2357.

53 Onai T, Yu JK, Blitz IL, Cho KW and Holland LZ (2010) Opposing Nodal/Vg1 and BMP signals mediate...
axial patterning in embryos of the basal chordate amphioxus. *Dev Biol* **344**, 377–389.

54 Kwong FN, Hoyland JA, Evans CH and Freemont AJ (2009) Regional and cellular localisation of BMPs and their inhibitors’ expression in human fractures. *Int Orthop* **33**, 281–288.

55 Tardif G, Pelletier JP, Hum D, Boileau C, Duval N and Martel-Pelletier J (2006) Differential regulation of the bone morphogenic protein antagonist chordin in human normal and osteoarthritic chondrocytes. *Ann Rheum Dis* **65**, 261–264.

56 Troilo H, Zuk AV, Tuniccliffie RB, Wohl AP, Berry R, Collins RF, Jowitt TA, Sengle G and Baldock C (2014) Nanoscale structure of the BMP antagonist chordin supports cooperative BMP binding. *Proc Natl Acad Sci USA* **111**, 13063–13068.

57 Piccolo S, Agius E, Lu B, Goodman S, Dale L and De Robertis EM (1997) Cleavage of Chordin by Xoloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. *Cell* **91**, 407–416.

58 Troilo H, Barrett AL, Wohl AP, Jowitt TA, Collins RF, Bayley CP, Zuk AV, Sengle G and Baldock C (2015) The role of chordin fragments generated by partial tolloid cleavage in regulating BMP activity. *Biochem Soc Trans* **43**, 795–800.

59 Troilo H, Barrett AL, Zuk AV, Lockhart-Cairns MP, Wohl AP, Bayley CP, Dajani R, Tuniccliffie RB, Green L, Jowitt TA et al. (2016) Structural characterization of twisted gastrulation provides insights into opposing functions on the BMP signalling pathway. *Matrix Biol* (in press). doi: 10.1016/j.matbio.2016.01.019

60 Xie J and Fisher S (2005) Twisted gastrulation enhances BMP signaling through chordin dependent and independent mechanisms. *Development* **132**, 383–391.

61 Plouhinec JL, Zakin L, Moriyama Y and De Robertis EM (2013) Chordin forms a self-organizing morphogen gradient in the extracellular space between ectoderm and mesoderm in the Xenopus embryo. *Proc Natl Acad Sci USA* **110**, 20372–20379.

62 Ashe HL and Levine M (1999) Local inhibition and long-range enhancement of Dpp signal transduction by Sog. *Nature* **398**, 427–431.

63 Ben-Zvi D, Shilo BZ, Fainsod A and Barkai N (2008) Scaling of the BMP activation gradient in Xenopus embryos. *Nature* **453**, 1205–1211.

64 Sawala A, Sutcliffe C and Ashe HL (2012) Multistep molecular mechanism for bone morphogenetic protein extracellular transport in the Drosophila embryo. *Proc Natl Acad Sci USA* **109**, 11222–11227.

65 Mason ED, Konrad KD, Webb CD and Marsh JL (1994) Dorsal midline fate in Drosophila embryos requires twisted gastrulation, a gene encoding a secreted protein related to human connective tissue growth factor. *Genes Dev* **8**, 1489–1501.

66 Oelschlegler M, Reversade B, Larraín J, Little S, Mullins MC and De Robertis EM (2003) The pro-BMP activity of Twisted gastrulation is independent of BMP binding. *Development* **130**, 4047–4056.

67 Oelschlegler M, Larraín J, Geissert D and De Robertis EM (2000) The evolutionarily conserved BMP-binding protein Twisted gastrulation promotes BMP signalling. *Nature* **405**, 757–763.

68 Yu K, Srinivasan S, Shimmi O, Biels B, Rashka KE, Kimelman D, O’Connor MB and Bier E (2000) Processing of the Drosophila Sog protein creates a novel BMP inhibitory activity. *Development* **127**, 2143–2154.

69 Schmidl M, Adam N, Surmann-Schmitt C, Hattori T, Stock M, Dietz U, de Crombrugghe B, Poschi E and von der Mark K (2006) Twisted gastrulation modulates bone morphogenetic protein-induced collagen II and X expression in chondrocytes in vitro and in vivo. *J Biol Chem* **281**, 31790–31800.

70 Zakin L and De Robertis EM (2004) Inactivation of mouse Twisted gastrulation reveals its role in promoting Bmp4 activity during forebrain development. *Development* **131**, 413–424.

71 Ikeya M, Nosaka T, Fukushima K, Kawada M, Furuta Y, Kitamura T and Sasai Y (2008) Twisted gastrulation mutation suppresses skeletal defect phenotypes in Crossveinless 2 mutant mice. *Mech Dev* **125**, 832–842.

72 Lorda-Diez CI, Montero JA, Diaz-Mendoza MJ, Garcia-Porrero JA and Hurle JM (2011) Defining the earliest transcriptional steps of chondrogenic progenitor specification during the formation of the digits in the embryonic limb. *PLoS One* **6**, e24546.

73 Lin X, Shanmugasundaram S, Liu Y, Derrien A, Nurminskaya M and Zamora PO (2012) B2A peptide induces chondrogenic differentiation in vitro and enhances cartilage repair in rats. *J Orthop Res* **30**, 1221–1228.

74 Wakefield LM, Smith DM, Flanders KC and Sporn MB (1988) Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. *J Biol Chem* **263**, 6764–6765.

75 Miyazono K, Hellman U, Wernstedt C and Heldin CH (1988) Latent high molecular weight complex of transforming growth factor beta 1 from human platelets. A high molecular weight complex containing precursor sequences. *J Biol Chem* **263**, 6407–6415.

76 Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L and Heldin CH (1990) TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. *Cell* **61**, 1051–1061.
77 Miyazono K, Olofsson A, Colosetti P and Heldin CH (1991) A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. *EMBO J* 10, 1091–1101.

78 Dabovic B, Chen Y, Colarossi C, Obata H, Zambuto L, Perle MA and Rifkin DB (2002) Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. *J Cell Biol* 156, 227–232.

79 Todorovic V, Finnegan E, Freyer L, Zilberberg L, Ota M and Rifkin DB (2011) Long form of latent TGF-beta binding protein 1 (Ltbp1L) regulates cardiac valve development. *Dev Dyn* 240, 176–187.

80 Nunes I, Gleizes PE, Metz CN and Rifkin DB (1997) Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. *J Cell Biol* 136, 1151–1163.

81 Delolme F, Anastasi C, Alcaraz LB, Mendoza V, Vadon-Le Goff S, Talantikite M, Capomaccio R, Mevaere J, Fortin L, Mazzocut D et al. (2015) Proteolytic control of TGF-beta co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics. *Cell Mol Life Sci* 72, 1009–1027.

82 Horiguchi M, Ota M and Rifkin DB (2012) Matrix control of transforming growth factor-beta function. *J Biochem* 152, 321–329.

83 Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X and Munger JS (2007) Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. *J Cell Biol* 176, 787–793.

84 Fontana L, Chen Y, Prijatelj P, Sakai T, Fassler R, Sakai LY and Rifkin DB (2005) Fibronectin is required for integrin alphaVbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. *FASEB J* 19, 1798–1808.

85 Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T and Springer TA (2011) Latent TGF-beta structure and activation. *Nature* 474, 343–349.

86 Buscemi L, Ramonet D, Klingberg F, Formey A, Smith-Clerc J, Meister JJ and Hinz B (2011) The single-molecule mechanics of the latent TGF-beta1 complex. *Curr Biol* 21, 2046–2054.

87 Annes JP, Chen Y, Munger JS and Rifkin DB (2004) Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. *J Cell Biol* 165, 723–734.

88 Yu Q and Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. *Genes Dev* 14, 163–176.

89 Saharinen J and Keski-Oja J (2000) Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBP5, creates a hydrophobic interaction surface for binding of small latent TGF-beta. *Mol Biol Cell* 11, 2691–2704.

90 Dabovic B, Robertson IB, Zilberberg L, Vassallo M, Davis EC and Rifkin DB (2015) Function of latent TGFbeta binding protein 4 and fibulin 5 in elastogenesis and lung development. *J Cell Physiol* 230, 226–236.

91 Inoue T, Ohbayashi T, Fujikawa Y, Yoshida H, Akama TO, Noda K, Horiguchi M, Kameyama K, Hata Y, Takahashi K et al. (2014) Latent TGF-beta binding protein-2 is essential for the development of ciliary zonule microfibrils. *Hum Mol Genet* 23, 5672–5682.

92 Menz C, Parsi MK, Adams JR, Sideek MA, Kopeczi Z, Cowin AJ and Gibson MA (2015) LTBP-2 has a single high-affinity binding site for FGF-2 and blocks FGF-2-induced cell proliferation. *PLoS One* 10, e0135577.

93 Sideek MA, Menz C, Parsi MK and Gibson MA (2014) LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, and is a negative modulator of elastogenesis. *Matrix Biol* 34, 114–123.